Microdacyn Wound Care solution is now available as a funded item on the Pharmaceutical Benefits Scheme (PBS) for RPBS relevant patients. Currently the RPBS is the only Australian government mechanism to fund wound care related products in the community.
“We are very pleased to have successfully achieved a funded listing in Australia for a certain group of people. The process for the listing was extensive and we look forward to further funding for wound care products in the future” commented Lance Gravatt, Chairman of Te Arai BioFarma.
Wound care and chronic wounds in Australia represent a significant healthcare burden and a significant health budget cost. Groups including Diabetic Foot Australia and the Wounds Australia are working toward securing government funding to improve wound-related outcomes across the population.
Microdacyn is a relatively new technology in Australia which acts to prevent and manage wound infection, reduce inflammation and significantly improve time to wound healing.
The PBS listing of Microdacyn is available here
Clinical details of Microdacyn are available for healthcare professionals here